Cases & Deals

  • Home
  • Practices
  • Junshi and Revitope team up for TEAC molecules through development, license, and equity

Share

Junshi and Revitope team up for TEAC molecules through development, license, and equity

July 2020

Client(s) Shanghai Junshi Biosciences Co., Ltd.

Jones Day represented Shanghai Junshi Biosciences Co., Ltd. in a research collaboration and license agreement with Revitope Oncology Inc. and its subsidiary to collaborate in the research and development of T-cell engaging cancer immunotherapies that utilize Junshi's antibody technology platform with Revitope's proprietary dual-antigen targeting technology platform. Junshi will designate up to 5 T-cell immunotherapeutic molecules. Revitope will receive a combination of development and commercialization milestones and tiered royalties on net sales. In addition, Junshi committed an equity investment into Revitope for up to 9.99% of its shares on an as-converted basis.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.